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Abstract 
Background: Sexually transmitted infections (STIs) are known risk factors for HIV 
infection. 
Goal: The goal of this study was to assess the current and potential future role that 
community pharmacists in Western Cape, South Africa play in the treatment of STIs. 
Study Design: A cross-sectional survey of community pharmacists in the Western Cape 
region of South Africa. A face-to-face interview that ascertained experience with requests 
from patients for STI treatment, current STI treatment practices, and willingness to 
provide syndromic STI treatment was administered to head pharmacists. 
Results: Ninety pharmacies were selected and 85 (94%) of the head pharmacists 
participated; 55 from an urban area and 30 from a rural area. Pharmacists reported a 
median of 40 urban clients and 25 rural clients who sought STI treatment from 
community pharmacists. When provided with a hypothetical clinical situation, 13% of 
urban and 17% of rural pharmacists identified the correct medication for male urethral 
discharge, 8% of urban pharmacists and none of the rural pharmacists identified correct 
treatment for genital ulcers, and none of the pharmacists identified the correct 
medication for vaginal discharge. Fifty-three percent of pharmacists in urban regions 
and 47% of pharmacists in rural regions expressed willingness to provide syndromic STI 
treatment. Independent predictors of willingness to provide syndromic treatment were 
knowledge of the link between HIV transmission and STIs (adjusted odds ratio [OR]: 
13.78; 95% CI: 2.69, 70.66), past experience prescribing syndromic STI treatment (OR: 
11.1; 95% CI: 1.14, 108.6), and male gender (OR: 4.38; 95% CI: 1.15, 
16.7). 
Conclusions: Pharmacists are frequently called upon to  provide STI treatment but have 
limited knowledge of correct treatment recommendations. Training pharmacists to 
provide syndromic STI treatment may be one strategy to reduce STI morbidity and 
HIV transmission. 
 
South Africa has one of the world’s most severe HIV-1 epidemics: an estimated 4.7 
million South Africans are infected with HIV, including 21.1% of adults aged 15 to 49 
years.1 Along with HIV, sexually transmitted infections (STIs) are highly prevalent in 
South Africa, with approximately 11 million new cases treated each year. Because STIs 
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are known to increase the risk of transmitting HIV infection,3,4  the South African 
Department of Health developed  an  HIV/AIDS/STI  strategic  plan  for  2000  to  2005, 
which calls for expanded efforts to treat and control STIs. One strategy for the control 
of STIs in developing countries is the use of syndromic treatment, which any healthcare 
worker may be trained to use. The plan specifies the need to ensure effective 
syndromic management of STIs in both the private and public sector. 
 
The majority of South Africans rely on publicly provided healthcare services, which are 
inadequately funded and staffed. This may explain the anecdotal reports suggesting 
that patients seek and receive treatment for STIs from pharmacists, despite legal 
restrictions to this practice (Medicine and Related Substances Control Amendment Act 
of 1997), a phenomenon that is also reported in other developing countries such as 
Ghana and Peru. Thus, pharmacists may represent an alternative source of care for the 
treatment of STIs in a setting in which the healthcare system is overburdened. To 
understand the current and potential role that pharmacists play in the treatment of 
STIs, we conducted a survey of community pharmacists in urban and rural areas of the 
Western Cape region of South Africa. Rigorous HIV prevention strategies are desperately 
needed in the Western Cape, where STI incidence is high and HIV prevalence is still 
relatively low. 
 
Methods 
A list of all community pharmacies located in the Western Cape was obtained from the 
South African Pharmacy Council. Pharmacies were stratified into those located in the 
Cape Metropole, an urban area (population density 1,125.74/km2), and those located in 
the rural area outside of the Cape Metropole (population density 11.39/km2). A simple 
random sample of pharmacies was selected from each stratum, proportional in size to 
the number pharmacies in each region. 
 
The owner or manager of selected pharmacies was contacted by telephone by one of the 
study staff and informed of the study purpose and procedures. Only lead pharmacists, 
all of whom hold a bachelor of pharmacy degree or higher, were interviewed because 
discussions regarding use of prescription medications only occur between the clients 
and lead pharmacists or, in rare situations, a nurse based in the pharmacy. An 
appointment was made to conduct the face-to-face interview with those pharmacists 
who agreed to participate. Signed consent to participate was obtained in person 
immediately before conducting the interview. 
 
Participating pharmacists were administered a structured interview that addressed the 
following key areas: (1) the characteristics of their pharmacies and clientele; (2) their 
knowledge, attitudes, and practices regarding STI management; and (3) their perceived 
obstacles to providing syndromic STI management. The Committees on Human 
Research of the University of California San Francisco and the University of Western 
Cape reviewed and approved this study. 
 
Analysis 
The chi-square test was used to identify statistically significant proportional differences 
between the characteristics of the pharmacies and the differences in the knowledge, 
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attitudes, and practices regarding syndromic STI treatment between the pharmacists 
who worked in urban and rural pharmacies. Wilcoxon rank sum test was used to 
compare differences in medians. 
 
Pharmacists were asked about their willingness to provide each individual step in the 
syndromic treatment of STIs. For the purposes of analysis, a pharmacist was defined as 
willing to provide syndromic STI treatment if he or she was willing to perform history 
taking, counseling for STI/HIV, partner notification, and follow-up, plus at least two of 
the following steps: visual or physical examination of genitals, prescribing medications, 
and phlebotomy for syphilis serology. We used this definition of willingness to provide 
syndromic treatment because these elements are required in the national STI syndromic 
treatment protocols. 
 
Logistic regression was performed to measure the association between the pharmacists’ 
willingness to provide syndromic treatment for STI and several predictor variables. The 
variables evaluated were the socioeconomic status of the clientele of the pharmacies, the 
location of the pharmacy (urban or rural), the gender of the pharmacist, the presence of a 
nurse at the pharmacy, the pharmacist’s perception of the need for syndromic STI 
treatment, having received requests for dispensing medication for the treatment of vaginal 
discharge, genital ulcers, and urethral discharge from clients, and knowledge of the 
existence of syndromic STI treatment protocols and Department of Health STI 
management guide. 
 
Pharmacists’ knowledge of STI treatment was gauged from their responses to three 
hypothetical case studies: a male patient with genital ulcers, a male patient with urethral 
discharge, and a patient with vaginal discharge. The responses were assessed against a 
standard for the correct management of STI6 and defined as “selected effective 
combination of therapies” if the selected treatment was consistent with these standards, 
and as “selected partially effective therapies” if at least one effective medication was 
selected. Other responses were not considered to be effective. 
 
For each of the clinical scenarios, the pharmacist was asked if he or she would “definitely,” 
“maybe,” or “not necessarily” refer the patient to a medical doctor, prescribe medication, 
and inform the client of HIV/AIDS risks. A response of definitely or maybe was 
considered to be affirmative. Pharmacists were classified as knowledgeable of the clinical 
and epidemiologic link between STI and HIV when HIV/AIDS risks were consistently 
mentioned in the three case studies. Among pharmacists who stated that they would 
provide medications for any of the clinical scenarios, the proportion that provided 
correct treatment (i.e., those who selected the correct combination of antibiotics as 
defined in national protocols) and partially correct treatment (selected at least one 
recommended antibiotic) was determined. 
Results 
 
Of the 406 community pharmacies located in the Western Cape, 90 (22%) were sampled 
and 85 (94%) agreed to be interviewed. Participating pharmacists from urban regions 
were more likely to be male than were pharmacists from rural regions (P < 0.001, 
Table1). Pharmacies in both regions had fairly extensive hours of operation. Clientele 
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represented diverse levels of income as described by the pharmacists, and this 
diversity did not differ between urban and rural pharmacies. Pharmacists reported 
receiving requests for medications without a doctor’s prescription on a frequent basis, 
including requests for treatment of STI; urban pharmacists reported significantly more 
requests for STI treatment in the previous 4 weeks than did rural pharmacists. 
 
In general, pharmacists regarded their role in the management of STI as underutilized, 
and the majority also strongly or slightly agreed that there is a need for STI treatment 
services to be provided in community pharmacies (Table 2). In both regions, a large 
proportion of the pharmacists indicated willingness to participate in syndromic 
treatment of STI. More than 90% of pharmacists from both regions were willing to take 
a history, counsel clients on prevention of STI and HIV, conduct partner-notification 
counseling, and follow up with the patient. Although all of the pharmacists in urban 
regions were willing to prescribe STI medication, fewer (87%) pharmacists in rural 
regions were willing to do so (P = 0.01). Almost half of pharmacists in both regions were 
willing to conduct visual inspection of the genitals, but only eight pharmacists in urban 
regions and none from rural regions were willing to conduct a physical examination of the 
genitals (P = 0.05). Most pharmacists were not willing to perform syphilis serology. 
 
Familiarity either with the STI syndromic management approach or with the 
Department of Health syndromic STI management guidelines was limited among 
pharmacists from both regions. When presented with three clinical STI scenarios, most 
of the pharmacists responded that they would refer the patient to a doctor and would 
provide counseling on HIV risk reduction. However, when compared with pharmacists 
in the urban regions, a significantly smaller proportion of rural pharmacists would 
counsel these patients (P = 0.01). Although few pharmacists would provide medication 
for male genital ulcer disease, many would treat male urethral discharge (58% urban 
pharmacists and 40% of rural pharmacists). More than 70% of pharmacists from both 
regions indicated that they would provide medication for vaginal discharge. Importantly, 
of those who would provide medication, very few were able to select the correct 
syndromic treatment. 
 
In bivariate logistic regression analyses of willingness of pharmacists to provide 
syndromic STI treatment, statistically significant variables were male gender of the 
pharmacist, having received prior requests from clientele for dispensing treatment for 
male genital ulcers without a prescription, knowledge of the existence of syndromic STI 
treatment protocols, and affirmative responses to the clinical scenarios in which the 
pharmacist would counsel the patient regarding the link between HIV and STI. 
 
In multivariate analysis, three independent associations with pharmacists’ willingness to 
treat STI were identified. Pharmacists were more likely to be willing to treat STI if they 
were aware of the HIV/STI link (odds ratio [OR]: 13.8; 95% CI: 2.7, 70.7) and if they had 
used they had used the syndromic STI management approach in the past (OR: 11.1; 95% 
CI: 1.1, 108.6). Of note, the effects of knowledge of the STI/HIV link and previous use 
of syndromic STI treatment were not additive (interaction term OR: 0.07; 95% CI: 0.01, 
0.97). Women pharmacists were significantly less likely to treat STI (OR 0.23; 95% CI: 
0.06, 0.87). 
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Pharmacists reported substantial obstacles to conducting STI treatment. The most 
frequently cited barriers were the current legal restrictions to pharmacists prescribing 
medication (97.6%), lack of skills in phlebotomy (97.6%), and conducting visual (83.5%) 
and physical examinations (91.7%). 
 
 
 
Discussion 
Our study confirms anecdotal reports that a high volume of possible STI is seen in 
community pharmacies with requests for medication without prescriptions. 
Furthermore, many community pharmacists recognize the relationship between HIV 
infection and other STIs, regard their role in treating STI as underutilized, and are 
willing to provide STI treatment. However, pharmacists cited current legal restrictions 
and lack of skills as significant barriers to providing such treatment. In addition, the 
pharmacists surveyed demonstrated a poor understanding of correct syndromic STI 
treatment protocols. Similarly, poor understanding of recommended treatment 
protocols was found in an intervention study in Peru in which pharmacies were 
randomized into those that were provided with syndromic treatment algorithms and 
those that did not receive training. When presented with research staff posing as 
patients, less than 16% of the pharmacists in the intervention or control groups 
provided the recommended treatment. However, the study in Peru did not assess 
pharmacists’ willingness to receive training and provide treatment; in fact, only 56% of 
the pharmacists who were offered training received any. In our study, approximately 
half of the pharmacists surveyed were willing to provide treatment. Therefore, methods to 
increase pharmacists’ participation in STI syndromic training programs need to be 
developed. 
 
Contrary to our expectations, the pharmacist’s perception of the need for STI services to 
be provided in pharmacies was not associated with their willingness to treat STIs; rather, 
the strongest predictor of their willingness to provide treatment was their knowledge of 
the relationship between STI and HIV infection. It is worth noting that of the steps 
included in syndromic treatment of STIs, pharmacists were generally willing to conduct 
all except examination and phlebotomy. Thus, if pharmacists were to be trained to 
provide STI treatment, efforts to overcome this barrier through specific education and 
training would need to be implemented. However, because of the difficulty associated 
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with training pharmacists in conducting physical examinations, phlebotomy, and 
biosafety, modified protocols in which the pharmacist relied on the patients’ clinical 
history, possibly with visual inspection of the genital region, would need to be 
developed and evaluated. Furthermore, lifting of the current legal restrictions that 
prevent pharmacists from prescribing medication is necessary. 
 
This study has several limitations. We sampled only 90 pharmacies; however, this does 
represent 22% of the target population. In addition, response bias may have been 
introduced, given the legal context of some of the practices of pharmacists. Some of the 
information collected may not be accurate, particularly the data concerning client 
characteristics (e.g., income level), for which we relied on pharmacists’ observations and 
impressions. In addition, we did not ascertain information that would allow us to assess 
an association between the pharmacists’ willingness to provide treatment and the various 
monetary benefits associated with syndromic treatment. Provision of certain 
medications may have a greater financial benefit to the pharmacists, which might 
increase willingness to provide treatment. We requested information on the number of 
clients requesting treatment without a prescription, but did not ascertain the overall 
number of patrons seen at the pharmacies because many people purchase items 
unrelated to prescription medications; this limited our ability to determine the proportion 
of clients who attended the pharmacies who requested treatment without a prescription 
Also, it should be noted that the reported average STI vaginal discharge caseload is 
probably an overestimation, given that every vaginal discharge, regardless of etiology, 
was considered to be an STI. However, because these factors did not contribute 
significantly to our results, it is unlikely that they invalidate our findings. 
 
Despite these limitations, our study points to a potentially powerful intervention to 
increase STI treatment coverage and hence reduce HIV transmission. Licensed 
pharmacists in South Africa have attained a high level of education in the health field, 
and it is likely that they can be trained to provide appropriate treatment and referrals for 
common STI syndromes. Factors such as the volume of patients requesting STI 
treatment, the availability of other local health services, and pharmacists’ willingness to be 
trained could be used to target those pharmacists where training and provision of 
treatment would be most efficient. We believe that the training and evaluation of 
pharmacists to provide syndromic treatment of STIs may help in the control of STI and 
contribute to a reduction in HIV transmission. 
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